If you have been reading about 胸腺素α1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
== Career == Bhatia began her academic career in 1998, joining the bioengineering faculty at the University of California, San Diego (UCSD). As an assistant professor, she was awarded a five-year Packard Fellowship for Science and Engineering from the David and Lucile Packard Foundation in 1999. She was recognized with a "Teacher of the Year" award at the Jacobs School of Engineering in 2001, and was named an "Innovator under 35" by MIT Technology Review in 2003. Bhatia co-authored the first undergraduate textbook on tissue engineering, Tissue engineering (2004), written for senior-level and first-year graduate courses with Bernhard Palsson. She was a co-editor of Microdevices in Biology and Medicine (2009) and Biosensing: International Research and Development (2005). In 2005, she joined the MIT faculty in the Division of Health Sciences & Technology and the Department of Electrical Engineering and Computer Science. The Scientist named her a "Scientist to Watch" in 2006, and she became a Howard Hughes Medical Institute Investigator in 2008. Since 2013, Bhatia has expanded her affiliations within MIT and Harvard, including the Ludwig Center for Molecular Oncology (2013), the Broad Institute of MIT and Harvard (2014), the MIT Center for Neurobiological Engineering (2016), the Wyss Institute for Biologically Inspired Engineering (2018), and the Martin Trust Center for MIT Entrepreneurship (2022). Bhatia currently directs the Laboratory for Multiscale Regenerative Technologies and the Marble Center for Cancer Nanomedicine at MIT.
In November 2004, club doctor Riccardo Agricola was given a 22-month prison sentence and fined €2,000 for sporting fraud by providing performance-enhancing drugs, specifically EPO, to players between 1994 and 1998, Leading hematologist Giuseppe d'Onofrio said that it was "practically certain" that midfielders Antonio Conte and Alessio Tacchinardi had taken EPO to overcome brief bouts of anemia, and that it was "very probable" that seven other players – Alessandro Birindelli, Alessandro Del Piero, Didier Deschamps, Dimas, Paolo Montero, Gianluca Pessotto and Moreno Torricelli – had taken EPO in small doses. In April 2005, the Court of Arbitration for Sport gave the following advisory opinion, in part: "The use of pharmaceutical substances which are not expressly prohibited by sports law, and which cannot be considered as substances similar or related to those expressly prohibited, is not to be sanctioned by disciplinary measures. However, regardless of the existence or not of any judgement rendered by a State court, sports authorities are under the obligation to prosecute the use of pharmaceutical substances which are prohibited by sports law or any other anti-doping rule violation in order to adopt disciplinary measures." In December 2005, Agricola was acquitted of the charges by Turin's court of appeal.
Rogue taxidermy (sometimes referred to as "taxidermy art" or "botched taxidermy") is a form of mixed media sculpture. Rogue taxidermy art references traditional trophy or natural history museum taxidermy, but is not always constructed out of taxidermied animals; it can be constructed entirely from synthetic materials. Additionally, rogue taxidermy is not necessarily figurative, as it can be abstract and does not need to resemble an animal. It can be a small decorative object or a large-scale room-sized installation. There is a very broad spectrum of styles within the genre, some of which falls into the category of mainstream art. "Rogue taxidermy" describes a wide variety of work, including work that is classified and exhibited as fine art. Neither the term, nor the genre, emerged from the world of traditional taxidermy. The genre was born from forms of fine art that utilize some of the components found in the construction of a traditional taxidermy mount. The term "rogue taxidermy" was coined in 2004 by an artist collective called The Minnesota Association of Rogue Taxidermists. The Minneapolis-based group was founded by artists Sarina Brewer, Scott Bibus, and Robert Marbury as a means to unite their respective mediums and differing styles of sculpture. The definition of rogue taxidermy set forth by the individuals who formed the genre (Brewer, Bibus, and Marbury) is: "A genre of pop-surrealist art characterized by mixed media sculptures containing conventional taxidermy-related materials that are used in an unconventional manner".
Sources: en.wikipedia.org
== History == BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
=== Middle Ages === After the fall of the Western Roman Empire, the town, along with the rest of the Italian peninsula, was conquered by the Heruli and the Ostrogoths, recaptured by the Romans, but then conquered again by the Lombards whose territory then fell into the hands of the Franks under Charlemagne (773). The Contea di Torino (countship) was founded in the 940s and was held by the Arduinic dynasty until 1050. After the marriage of Adelaide of Susa with Humbert Biancamano's son Otto, the family of the Counts of Savoy gained control. While the title of count was held by the Bishop as count of Turin (1092–1130 and 1136–1191) it was ruled as a prince-bishopric by the Bishops. In 1230–1235, it was a lordship under the Marquess of Montferrat, styled Lord of Turin. At the end of the 13th century, when it was annexed to the Duchy of Savoy, the city already had 20,000 inhabitants. Many of the gardens and palaces were built in the 15th century when the city was redesigned. The University of Turin was also founded during this period.
Russian President Vladimir Putin acknowledged that the "special military operation" was taking longer than expected but claimed the country's nuclear arsenal was preventing the conflict from escalating. As in June 2022, he made another reference to the expansion of the Russian Empire by Peter the Great. The Ukrainian General Staff claimed to have launched multiple strikes against Russian logistic lines near the cities of Berdyansk, Tokmak, Melitopol, Enerhodar, Dniprorudne, Polohy, and Vasylivka, Zaporizhia Oblast. They claimed 240 Russians were wounded and 20 pieces of military equipment were destroyed in the strikes.
Sources: en.wikipedia.org
Side effects are similar to those of morphine, but due to pentazocine's action at the κ-opioid receptor, it is more likely to invoke psychotomimetic effects. High dose may cause high blood pressure or high heart rate. It may also increase cardiac work after myocardial infarction when given intravenously and hence this use should be avoided where possible. Respiratory depression is a common side effect, but is subject to a ceiling effect, such that at a certain dose the degree of respiratory depression will no longer increase with dose increases. Albeit rarely, pentazocine has been associated with agranulocytosis, erythema multiforme and toxic epidermal necrolysis.
The side effects of elagolix are in general similar to menopausal symptoms. The most common side effects of elagolix (incidence ≥10%) are hot flashes, night sweats, headaches, nausea, and amenorrhea (cessation of menstruation). The next most frequent side effects of elagolix (incidence ≥5%) are insomnia, anxiety, arthralgia (joint pain), depression, and mood changes. Less common side effects of elagolix (incidence ≥3% and <5%) include decreased sex drive, diarrhea, abdominal pain, weight gain, dizziness, constipation, and irritability. Other common side effects of elagolix include decreased bone mineral density (BMD) and changes in the blood lipid profile. Rare but serious adverse effects that were observed during elagolix therapy in clinical trials included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%), though it is unknown if these were due to elagolix. Other serious adverse effects of elagolix may include bone loss, miscarriage, suicidality, and elevated liver enzymes. Elagolix was discontinued due to side effects by 5 to 10% of women in clinical trials, with the most common reasons being hot flashes or night sweats, nausea, and decreased BMD. Elagolix dose- and duration-dependently decreases BMD in premenopausal women with long-term therapy. After 6 months of treatment with elagolix, lumbar spine BMD was decreased by 0.3 to 1.3% with 150 mg once per day and by 2.5 to 3.1% with 200 mg twice per day.
=== Central === If the TSH level is normal or low and serum free T4 levels are low, this is suggestive of central hypothyroidism (not enough TSH or TRH secretion by the pituitary gland or hypothalamus, respectively). There may be other features of hypopituitarism, such as menstrual cycle abnormalities and adrenal insufficiency. There might also be symptoms of a pituitary mass such as headaches and vision changes. Central hypothyroidism should be investigated further to determine the underlying cause.
=== Period 3: final narrative evolution === The final stage at Kizil is Period 3 of the Second Indo-Iranian Style. Towards the end of its florescence, Kizil saw the emergence of the domed central pillar cave, a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic near-cubic main cella crowned by a magnificent cupola decorated with divinities. The style of painting is very refined, and can also be seen in some other caves in the region such as in Kumtura. The iconography too has evolved, with a cosmological Buddha becoming omnipresent and majestic, often surrounded by myriads of emanations of smaller Buddhas. This exceptional and very refined type of cave is exemplified by Cave 123, the "Cave with the Ring-Bearing Doves". It represents a final narrative evolution, in which the figures of the cosmological Buddha predominate, while secondary figures and stories take an ever-smaller role.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.